Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
carbplatin, cyclophophamide, atezolizumab · 1 trial · 4 indications
Adverse events will be graded according to NCI Common Toxicity Criteria version 4.03
| Arm | Type | Description |
|---|---|---|
| carbo, cyclo, atezolizumab | EXPERIMENTAL | The starting dose is carboplatin AUC 5mg/ml\*min (d1), cyclophosphamide 600mg/m2(d1) and atezolizumab 840 mg (D1, 15), all administered intravenously |
| Name | Type | Description |
|---|---|---|
| carbplatin, cyclophophamide, atezolizumab | DRUG | - |
Inclusion Criteria: * Histological or cytological proof of advanced breast cancer (M1) or advanced gynaecological cancer (cervix (M1, FIGO IVA/IVB), ovarian (only after recurrence on carboplatin and/or paclitaxel) stage 4 cervical or endometrial (T3-T4, FIGO IVA/IVB) cancer) pre-treated with maxima...
Top 20 of 92 competitors
Carboplatin, cyclophosphamide, and atezolizumab is a combination regimen being studied for the treatment of breast cancer. It is also being investigated for cervix cancer, ovarian cancer, and endometrial cancer. The combination is currently in Phase 1 clinical development and is considered investigational.
Roche Holding AG (ticker: RHHBY) is the developer of the carboplatin, cyclophosphamide, and atezolizumab combination regimen. The company is conducting clinical research on this combination for oncology indications, including breast cancer.
Carboplatin, cyclophosphamide, and atezolizumab is in Phase 1 clinical development. The combination is investigational and has not been approved by regulatory authorities. One Phase 1 trial has been completed, and the drug is not currently in active clinical trials.
Carboplatin, cyclophosphamide, and atezolizumab was studied in a completed Phase 1 trial with the identifier NCT02914470. The trial enrolled 12 participants and evaluated the combination in patients with breast cancer, cervix cancer, ovarian cancer, and endometrial cancer. The study was conducted in the Netherlands.
Carboplatin, cyclophosphamide, and atezolizumab is a combination regimen that includes atezolizumab along with the chemotherapy drugs carboplatin and cyclophosphamide. It is not the same as atezolizumab alone, as it combines multiple agents. The combination is being studied for its potential effects in certain cancers.